Press Releases April 28, 2026 09:54 AM

CORRECTION -- Sagtec Global to Announce Fiscal Year 2025 Financial Results on April 29, 2026

Sagtec Global Corrects Fiscal Year 2025 Earnings Announcement Date to April 29, 2026

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
SAGT

Sagtec Global Limited announced the corrected release date for its fiscal year 2025 financial results and conference call, now scheduled for April 29, 2026, instead of the previously stated date in 2025. The company plans to review its progress and financial outlook during the call.

CORRECTION -- Sagtec Global to Announce Fiscal Year 2025 Financial Results on April 29, 2026
SAGT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Sagtec Global Limited is a Nasdaq-listed technology company specializing in POS systems and enterprise software solutions.
  • The company is expanding into strategic operating assets to create vertically integrated revenue streams.
  • The fiscal year 2025 financial results will be announced on April 29, 2026, with a management earnings call following on the same day.

In a press release issued under the same headline earlier today by Sagtec Global Limited (NASDAQ: SAGT), the earnings announcement date and conference call date were incorrectly stated as April 29, 2025. The correct date is April 29, 2026. The corrected release follows:

Previous“We look forward to engaging with our investors and sharing the progress and growth achieved during fiscal year 2025,”
Next

KUALA LUMPUR, Malaysia, April 28, 2026 (GLOBE NEWSWIRE) -- Sagtec Global Limited (NASDAQ: SAGT) (“Sagtec” or the “Company”), today announced that it will release its financial results for fiscal year 2025, ended December 31, 2025, on April 29, 2026. Sagtec’s management team will hold earnings call at 09:00 a.m. Eastern Time on April 29, 2026, to discuss the Company’s financial and business outlook.

What: Sagtec Global Limited Announces Fiscal Year 2025 Financial Results and Q&A Webcast
When: Wednesday, April 29, 2026
Time: 9:00 a.m. Eastern Time / 9:00 p.m. Malaysia Time
Webcast: Registration link: https://edge.media-server.com/mmc/p/4yayxscx

Approximately 24 hours after the Q&A session, an archived version will be available on the Company’s website for approximately twelve months thereafter.

“We look forward to engaging with our investors and sharing the progress and growth achieved during fiscal year 2025,” said Kevin Ng, Chairman, Executive Director and Chief Executive Officer of Sagtec.

About Sagtec Global Limited

Sagtec Global Limited (NASDAQ: SAGT) is a Nasdaq-listed technology company specializing in POS systems and enterprise software solutions, now expanding into strategic operating assets to create vertically integrated revenue streams.

For more information on the Company, please log on to https://www.sagtec-global.com/.

Contact Information:

Sagtec Global Limited Contact:
Zainab Fateema binti Mustafa
Head of Public Relations & Corporate Affairs
Telephone +6011-6217 3661
Email: [email protected]


Risks

  • The correction of the announcement date may cause temporary uncertainty among investors.
  • As a tech company focusing on POS and software solutions, Sagtec faces market competition risks and the pace of technology adoption.
  • Expansion into new strategic assets introduces execution risks and integration challenges.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026